Innovent's PD-1 Approved in China for First-Line NSCLC Indication

Suzhou Innovent Biologics and its partner Eli Lilly announced China approved its supplemental NDA of their partnered anti-PD-1 drug, Tyvyt® (sintilimab injection), as a first-line treatment for nonsquamous non-small cell lung cancer. Tyvyt will be administered in combination with pemetrexed and platinum chemotherapy. In 2018, Tyvyt was first approved in China as a third-line treatment for Hodgkin's lymphoma. Innovent is conducting over 20 Tyvyt clinical studies, including more than 10 registrational or pivotal clinical trials. More details.... Stock Symbols: (HK: 01801) (NYSE: LLY) Share this with colleagues: // //